BioPharmSignal logoBioPharmSignal

Biotech News

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals (PHAT)Phathom PharmaceuticalsEarnings

~1.7 million total VOQUEZNA ® prescriptions filled to date Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 Q2 operating expenses of $63.1 million, reduced by 33% vs. Q2 2025 Initiating Phase 3 clinical trial evaluating as-needed dosing of VOQUEZNA ® in

Related news

PHATPhathom Pharmaceuticals2026-04-30 10:59 EST

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

PHATPhathom Pharmaceuticals2026-02-26 12:00 EST

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (Corrected)

View all latest news

Phathom Pharmaceuticals

Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker. VOQUEZNA Franchise VOQUEZNA is marketed in the United States for heartburn associated with non-erosive...

Recent company news

PHATPhathom Pharmaceuticals2026-07-30 10:59 EST

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

PHATPhathom Pharmaceuticals2026-07-20 12:00 EST

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

PHATPhathom Pharmaceuticals2026-06-23 11:59 EST

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

PHATPhathom Pharmaceuticals2026-05-22 12:00 EST

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

PHATPhathom Pharmaceuticals2026-05-20 12:00 EST

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Stock data

Close
8.39 USD
Market cap
769.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States